Start Page / Reports / Drotrecogin alfa (Xigris®) for severe sepsis

Drotrecogin alfa (Xigris®) for severe sepsis

Report type: Alert
Published: 2003-11-05
Contact person: Jan Liliemark  E-mail: liliemark@sbu.se

Findings by SBU Alert

Version: 1

Technology and target group

Sepsis is a life-threatening condition characterized by a systemic inflammatory response to infection. The condition is classified as severe sepsis if at least one vital organ system ceases to function. Septic shock is diagnosed when low arterial blood pressure that does not resolve with adequate fluid resuscitation occurs. Mortality is approximately 20 percent in cases of severe sepsis and 45 percent in cases of septic shock. Drotrecogin alfa (Xigris®) is a new drug approved August 2002 in Sweden as an adjunct to standard treatment of severe sepsis in adults. The estimated size of the target group is below 500 patients per year.

Patient benefits and risks

One randomized, placebo-controlled, double-blind, multicenter trial that compared drotrecogin alfa (Xigris®) to placebo was identified. The trial included 1 690 patients from 11 countries. Mortality at 28 days after the start of treatment was 30.8 percent in the placebo group and 24.7 percent in the treatment group, ie, an absolute risk reduction of 6.1 percentage units. The benefit was shown only for the most severely ill patients according to a severity of disease classification system (APACHE II). This suggests that 1 death per 16 treated patients could be avoided (NNT=16). The risk for severe hemorrhage in conjunction with treatment was 1.5 percent.

Economic aspects

The drug cost of drotrecogin alfa (Xigris®) is 85 000 Swedish kronor (SEK) per patient. Two studies have estimated cost effectiveness. Both of these studies have estimated the cost per life-year gained to be approximately 260 000 SEK and the cost per quality-adjusted life-year (QALY) to be approximately 400 000 SEK. If the calculation is based only on data for the most severely ill patients, the cost per life-year gained is estimated to be approximately 160 000 SEK and the cost per quality-adjusted life-year approximately 240 000 SEK.

Scientific evidence

Currently there is moderate* scientific evidence that show positive effects of drotrecogin alfa on survival in patients with severe sepsis. There is moderate* scientific evidence of its cost effectiveness. Results from long-term followup on the risks and benefits of treatment have yet to be published. Therefore, it is essential to systematically monitor clinical experiences at the national level.

*This assessment by SBU Alert uses a 4-point scale to grade the quality and evidence of the scientific documentation. The grades indicate: (1) good, (2) moderate, (3) poor, or (4) no scientific evidence on the subject.

This summary is based on a report prepared at SBU in collaboration with Sten Walther, MD, Örebro University Hospital and Thomas Nolin, MD, Centralsjukhuset, Kristianstad. It has been reviewed by Bengt Ljungberg, MD, Medical Products Agency.

The complete report is available only in Swedish.

SBU Alert is a service provided by SBU in collaboration with the Medical Products Agency, the National Board of Health and Welfare, and the Federation of Swedish County Councils.

References

  1. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31(1):1-11.
  2. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71.
  3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699-709.
  4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55. Review.
  5. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003;29(6):894-903.
  6. Gårdlund B, Sjölin J. Aktiverat protein C - ett nytillskott i sepsisbehandlingen. Läkartidningen 2003;100(26-27):2292-6. Review.
  7. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13(10):818-29.
  8. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347(13):993-1000.
  9. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 2003;18(4):217-27.
  10. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-77.
  11. Wenzel RP. Treating sepsis. N Engl J Med 2002;347(13):966-7.
  12. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340(3):207-14. Review.
  13. Anti-Infective Advisory Committee. Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] XigrisT. U.S. Food and Drug Administration. 2001. FDA briefing document. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.doc
  14. Hjelmgren J, Ragnarson Tennvall G, Persson U, Finnern HW, Myren K-J, The PROWESS Economic Team. Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in Sweden. (not published)